Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ViiV

- PMLiVE

CHMP backs shorter Cervarix schedule

Revised dosing could make running immunisation programmes with GSK's vaccine easier

- PMLiVE

FDA lifts restrictions on Avandia use

US regulator says GSK’s diabetes drug does not increase heart attack risk

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

GSK cashes in its stake in Africa’s Aspen

Sells 28.2 million shares

- PMLiVE

Grey/Ogilvy alliance wins two GSK accounts

WPP’s GO Team to lead on two antacid brands

- PMLiVE

GSK hit as darapladib flunks phase III test

Heart disease drug disappoints in late-stage trial

- PMLiVE

Electric dreams in medicine

Treating human disease with electrical impulses dates back decades, and now pharma is exploring the concept of ‘electroceuticals’ to complement drug-based therapy

- PMLiVE

GSK sets up centre to develop greener drugs

Brazil centre to focus on sustainable chemistry

- PMLiVE

China weighs heavy on GSK figures in Q3

Pharma company loses two thirds of sales in region after scandal-hit period

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links